

The Federation of European  
Scleroderma Associations

---

# ANNUAL REPORT 2024



# Table of contents

3

[Message from the President and Vice President](#)

4

[About FESCA](#)

6

What we did in 2024



[Awareness](#)



[Education](#)



[Healthcare](#)



[Research](#)

22

[Directory of Members](#)





# Message from the President and Vice President



We are delighted to present this report on FESCA's activities in 2024. Once again it was a busy year, with the World Scleroderma Congress in March and World Scleroderma Day in June being two of the key highlights.


After two virtual congresses, we were thrilled for the **8th Systemic Sclerosis Patient World Congress** to be held in-person in Prague between 14th-16th March, which welcomed hundreds of scleroderma patients, caregivers, clinicians, and researchers from around the globe. It was great to witness the exchange of ideas and camaraderie between attendees, and we are looking forward to the next Systemic Sclerosis Patient World Congress in 2026, which will be held in the vibrant city of Athens!

This year we continued to build on the momentum of the impactful **'Find the Light to Bloom' campaign**, which highlights the unmet needs of people living with scleroderma and the challenges they face regarding diagnosis, treatment and quality of life. The theme was about the need to expand access to multi-professional care under the banner of 'Empower Your Health Journey'. During this campaign we were able to continue utilising and disseminating the insights gathered in the comprehensive patient survey conducted in 2023. The campaign was a great success, with high engagement rates across all social media platforms and several impactful local initiatives run by our members. We've detailed the results and a few of the local initiatives later in this report.

We are pleased to welcome the Bulgarian Organization for **Patients with Rheumatic Diseases (BOPRD) as a new member of FESCA**. Their dedication strengthens our shared mission to support patients across Europe.

We look forward to continuing this important work throughout 2025 and want to thank all our members for their work throughout 2024.

Best wishes,  
Sue Farrington PRESIDENT



Ilaria Galetti VICE-PRESIDENT



# About FESCA

The Federation of European Scleroderma Associations (FESCA) is a pan-European umbrella organisation dedicated to promoting and achieving its objectives in alignment with the goals of the national groups it represents.

Scleroderma is a rare and highly diverse disease encompassing various manifestations of connective tissue and vascular disorders. The disease presents significant challenges in treatment and care due to limited awareness, disparities in healthcare systems, insufficient social support, isolation from specialists, and gaps in medical knowledge about available therapies.

To drive meaningful change, it is essential to foster support, advocacy, and research by engaging a broad community of stakeholders.

## Our mission:

Our mission is to provide information to people with scleroderma, increase awareness on an international level, and advocate for equitable treatments for people with scleroderma throughout Europe.

We pursue this mission by:

- Representing European national organisations.
- Engaging policymakers and industry.
- Collaborating with doctors to improve care and foster research.
- Promoting clinical, translational, and social research.
- Facilitating networking and collaboration.



**Umbrella group of 28 scleroderma patient organisations**



**Amplifying the voice of scleroderma patients**



**Empowering member organisations**



**Sharing the best practice**



## Our vision:

A world in which everyone with Scleroderma receives timely access to the same level of successful care from fully informed healthcare professionals, followed ultimately by a cure.

We envision a world where:

- Scleroderma is widely recognized as a serious condition.
- Society is aware of scleroderma, reducing the isolation felt by those affected.
- Patients have equal access to effective treatments.
- Medical professionals have better knowledge of, and access to, treatments.

Consistent, high-quality care is available for scleroderma patients worldwide.

## Looking ahead

FESCA remains committed to driving positive change for the scleroderma community through advocacy, collaboration, and innovation.

In March 2024, FESCA reinforced its strategy plan for the upcoming 3 years aimed at ensuring every scleroderma patient receives gold-standard therapy and care.

To achieve this, FESCA ambitions to advance in the following pillars:



**We advocate for equal and timely access to the highest standards of treatment and care for all.**



**We work to increase awareness of scleroderma among key stakeholder groups.**



**We aim to improve knowledge and understanding of scleroderma among the community of patients, caregivers, and healthcare professionals.**



**We support and promote the importance of both pharmacological and non-pharmacological treatments. We collaborate with industry to amplify the patient voice in drug development.**

# What we did in 2024

## Awareness



### World Scleroderma Day 2024 “Find the Light to Bloom - Empower Your Health Journey”

World Scleroderma Day, annually on June 29th, unites the global scleroderma community to honor the resilience of those affected by the disease and to advocate for improved access to comprehensive, multiprofessional care. Such care is essential for addressing the multifaceted nature of scleroderma.

FESCA continues its impactful campaign, which highlights the unmet needs. Improving access to multiprofessional care is vital in enhancing treatment outcomes and overall quality of life for individuals living with scleroderma. A holistic care model addresses the many dimensions of this complex and rare condition, which is essential for managing symptoms and slowing the disease’s progression. This integrated approach fosters a strong support network—empowering patients to take an active role in their care.



## Awareness

A key component of this campaign is to ensure access to multiprofessional care, which is essential for improving outcomes and quality of life for people with scleroderma. A coordinated approach that addresses medical, psychological, and social needs—including non-pharmacological treatments such as physiotherapy and psycho-social support—ensures patients receive truly holistic, person-centered care.

To make this care more accessible, adopting a hub-and-spoke model within national health systems, supported by telemedicine and digital health tools, helps bring specialised scleroderma services closer to patients.

To amplify the reach and impact of World Scleroderma Day, FESCA provides resources—including digital banners, posters, and social media materials—to facilitate awareness-raising activities.

By leveraging these tools, stakeholders can contribute to a unified effort to improve the lives of individuals living with scleroderma across Europe and beyond.

For more information and to access these resources, please visit FESCA's official [World Scleroderma Day 2024](#).

### Digital Campaign Performance Highlights

In 2024, FESCA continued its impactful "Find the Light to Bloom" campaign, raising awareness about the unmet needs of scleroderma patients. The campaign leveraged social media to amplify its message and engage diverse audiences:



## Awareness

- Posts for World Scleroderma Day on Facebook achieved a total reach of 112,723, with 111,248 video views and 844 link clicks.
  - The engagement rate for these posts stood at 2.34%, significantly exceeding the benchmark of 0.72%, highlighting the success of strategic promotion efforts.
- 
- World Scleroderma Day content reached 45,708 users, on Instagram with 42,774 reel views and an engagement rate of 6.04%.
  - Top-performing reels emphasized awareness and encouraged community involvement, receiving over 7,690 impressions and 2,466 engagements.
- 
- Posts achieved a reach of 16,915 on LinkedIn, with 2,900 video views and a 4.69% engagement rate, reflecting LinkedIn's strength in reaching policymakers and professional audiences.

Below are some examples of initiatives which took place at the national level.

### **Croatia: HUOS – Hrvatska udruga oboljelih od sklerodermije**

The Croatian Society for Patients with Scleroderma successfully organised an awareness campaign for the World Scleroderma Day on June 29th. The campaign kicked off with the distribution of informational materials prepared by FESCA.

## Awareness



The association's president, Jadranka Brozd, was actively involved in media appearances throughout the campaign. She participated in several radio and television programs, including guest appearances on shows such as "Mogu sve," "Izaberi zdravlje," and "Zdravi bili." Her participation helped spread awareness about scleroderma across various platforms, reaching a wider audience.

On June 22nd, the association hosted a special event in Krašograd for members and volunteers. The event included socializing, information sharing, and recording content for social media to further promote awareness.

The central event took place on June 29th in Zrinjevac, Zagreb. During the event, interviews were conducted, and media representatives had the opportunity to speak directly with association members and those affected by scleroderma. Educational materials, including a reel about scleroderma, were also published online.

The campaign included several other key activities, including the publication of an article about an association member, Andrea, on Zagreb.info. A promotional video on scleroderma was released, and the association continued to plan interviews with members throughout July to keep raising awareness.

---

### France - Association des Sclérodermiques de France

During June and July, the ASF's regional delegation supported a series of medical conferences organized across major cities in France. These conferences served as a platform to share knowledge and foster collaboration within the medical community.

## Awareness



In some locations, the events were enhanced by therapeutic education workshops, including sessions on make-up and physiotherapy, aimed at improving patients' quality of life.

The ASF also extended its reach by sharing social media posts from FESCA and the Swiss Association, helping to amplify awareness and promote shared initiatives within the broader scleroderma community.

---

### Germany - Sklerodermie Selbsthilfe e.V.

Sklerodermie Selbsthilfe e.V. organized an online course focused on fascia training. This initiative aimed to provide practical tools and techniques to help individuals manage the effects of scleroderma. The course offered valuable insights into fascia care, promoting improved mobility, reduced discomfort, and overall well-being for participants.



---

### Greece - Hellenic League Against Rheumatism

On June 29th, the Hellenic League Against Rheumatism issued a press release to raise awareness about Scleroderma and inform the public about the condition. This initiative was supported through updates on social media platforms and the organisation's website, ensuring broad dissemination of information and engagement with the community.

## Awareness

### Portugal - ADPE - Associação Portuguesa de Doentes com Esclerodermia

The ADPE organized a significant event that brought together patients, families, and healthcare professionals, fostering a sense of community and mutual understanding. This gathering served as an important platform for sharing knowledge, discussing challenges, and providing support to those affected by scleroderma.



To enhance the event's impact, the association shared the slogan and visuals through their social media, creating a cohesive and engaging identity. These efforts helped to raise awareness and ensure the message reached a wider audience while reinforcing ADPE's commitment to supporting the scleroderma community.

---

### Spain - Asociación Española de Esclerodermia

The main event of the AEE on this day was the celebration of the I National Congress of Scleroderma for patients in Valladolid, in the Archive of the Royal Chancery. At this congress, crucial topics for patients were addressed, such as research, diagnosis and other relevant aspects of this autoimmune disease. In addition, the AEE presented its decalogue entitled "Ideal care model for scleroderma care", which includes the needs and challenges of patients to access appropriate services and treatments, emphasizing the importance of collaboration between Public Administrations and society in general.

## Awareness

Throughout the month of June, AEE disseminated the FESCA awareness campaign in municipalities and cities, hanging the main poster of the campaign translated into Spanish: “Impulsa tu Bienestar – Encuentra la Luz para Brillar”.



---

### Sweden - The Swedish Rheumatism Association Reumatikerförbundet

The Swedish Rheumatism Association organised a conference that brought together 36 participants, creating an opportunity for learning, discussion, and connection among attendees.

A newsletter containing useful materials was distributed within the community. This ensured that the information reached a wider audience and provided ongoing resources for those interested in scleroderma.

---

### Switzerland - Sclerodermie.ch

In June, Sclerodermie.ch launched a dedicated effort to raise awareness about scleroderma. The campaign highlighted stories of hope and resilience, aiming to inspire and empower those affected by this rare disease. Through these efforts, the organization emphasized the importance of collective action in striving for a better future for the scleroderma community.

# Awareness

## United Kingdom - SRUK

SRUK launched a digital advertising campaign aimed at raising awareness and educating the public about Scleroderma. This initiative utilized online platforms to reach a wide audience and promote greater understanding of the condition.

---

### Digital Campaign Performance Highlights

#### Awareness





Raising awareness is a central pillar of FESCA, awareness efforts not only help educate the public and healthcare professionals about this rare and complex disease, but also strengthen advocacy efforts by giving visibility to patient voices at both national and European levels.

Social media serves as a powerful tool to amplify these efforts. By engaging online communities, FESCA and its member organisations can reach wider audiences, and ensure that the scleroderma community is seen, heard, and represented.

#### Social Media Content

To support awareness throughout 2024, FESCA developed and distributed high-quality, evergreen social media content for its member associations. This content enabled a consistent and professional presence across platforms.

Key achievements in 2024 included:

-  Development of 11 monthly content calendars (February to December)  
Creation of up to 10 social media posts per month focused on key topics, awareness dates and events.
-  Copywriting in English, with local market teams handling translations
-  Platform-specific adaptations for Facebook, Instagram, and LinkedIn
- 

This structured approach helped member associations maintain a strong digital presence and reinforce FESCA's collective voice across Europe.

## Education

### 8th Systemic Sclerosis Patient World Congress (March 14–16, 2024, Prague)



The biannual **Systemic Sclerosis Patient World Congress** was designed by patients and for patients. Our congress is focused on educating and empowering patients and the SSc community, embodying FESCA's dedication to patient and public education as a key strategic priority. After two virtual editions due to the COVID-19 pandemic, this event was held in person in Prague, Czech Republic, from 14-16 March. It was held alongside the medical congress organized by the World Scleroderma Foundation, the event encouraged collaboration between patients and healthcare professionals, promoting greater mutual understanding and support.

The programme of the 8th Systemic Sclerosis Patients World Congress featured scleroderma patients as both speakers and moderators, who shared the stage with renowned healthcare professionals (HCPs) in the field. The event aimed to facilitate an informative and accessible exchange of knowledge, with sessions designed for a general audience.



## Education



Topics included the latest research, treatment options, and personal experiences, ensuring attendees gained valuable insights to empower them in their own scleroderma journey.

In addition to the engaging patient programme, all participants were invited to the official opening of the medical congress on the evening of 14th March.

Furthermore, FESCA member association representatives took part in the FESCA Members Meeting earlier that day, where they networked and discussed the unmet needs and challenges faced by scleroderma patients, identifying areas where FESCA could focus its advocacy efforts.

This biannual hallmark event brought together more than 180 attendees from over 20 countries, including patients, caregivers, clinicians, and researchers. For the first time since the COVID-19 pandemic, the congress returned to an in-person format, fostering collaboration between patients and healthcare professionals.

### Key Sessions and Highlights:

#### 1- "Handy Solutions: Managing Hand Changes in SSC"

- This session addressed practical and clinical approaches to managing Raynaud's phenomenon, ulcers, and calcinosis in scleroderma patients.
- Speakers emphasized physiotherapy, early rehabilitation, and innovative treatments to prevent disease progression. Patient perspectives were shared to highlight the daily challenges and coping strategies.



## Education

### 2- "The Gut Microbiome and Scleroderma"

- Experts discussed the impact of gastrointestinal symptoms on patients' lives and explored potential interventions, such as probiotics and personalized dietary plans.
- The session also delved into the role of gut microbiota in autoimmune diseases and emerging therapies like fecal microbiota transplantation (FMT).



### 3- "Breaking Ground: Advances in Systemic Sclerosis Research"

- Speakers presented cutting-edge research on early diagnosis, disease biomarkers, and novel therapies such as CAR-T cell treatments.
- Discussions underscored the importance of clinical trials, patient-reported outcomes, and evolving pharmaceutical strategies to improve patient care.

### 4- "Mental Health and Scleroderma"



- This session explored the psychological toll of living with SSc, including depression, anxiety, and coping mechanisms.
- Patients shared personal stories, while experts outlined approaches to mental health support, emphasizing the importance of integrating psychological care into treatment plans.

### Participant Feedback and Success Metrics:

- 85.4% of attendees rated the program as excellent or good, with 61% strongly agreeing that the event met their expectations.
- Favorite sessions included "Handy Solutions" and "The Gut Microbiome in SSc."
- Attendees liked the congress for its diversity of sessions, networking opportunities, and the inclusion of patient voices.

## Education

For more information, please visit FESCA's official [8th Systemic Sclerosis Patient World Congress page](#).

# 8<sup>TH</sup> SYSTEMIC SCLEROSIS PATIENT WORLD CONGRESS

MARCH 15-16, 2024  
PRAGUE, CZECH REPUBLIC

### Looking ahead:

FESCA is committed to advancing its mission in 2025 and beyond. Plans include:

Hosting the 9th Systemic Sclerosis Patient World Congress in Athens, Greece (2026).

Strengthening advocacy campaigns to promote equitable access to care.

# Healthcare





## Patient Group Advocacy Toolkit

Advocacy remains at the core of FESCA's mission. In 2024, we strengthened this commitment by launching the FESCA Advocacy Toolkit and hosting an accompanying online webinar to support our members in their national and regional advocacy efforts.

The Toolkit was developed specifically for FESCA members as a practical and strategic guide to help navigate the complexities of advocacy. Whether engaging with policymakers, running impactful awareness campaigns, or increasing visibility on social media, the aim was to provide the tools and confidence needed to influence real change. It offered clear, actionable guidance on how to participate in the policy-making process, build effective relationships with decision-makers, and raise the visibility of scleroderma across all stakeholder groups.

At its heart, the Toolkit reflects FESCA's broader strategic objective: to ensure the voices of people affected by scleroderma are heard and considered in healthcare decisions across Europe.

### Objectives of the Toolkit:

-  Providing comprehensive guidance on the fundamentals of advocacy, helping to understand what advocacy involves and how it can significantly impact their goals.
-  Helping navigate the often complex and dynamic policy landscape, offering insights into how policy-making bodies function, how decisions are made and influenced.
-  Offering practical tips for building relationships with key decision makers, ensuring patients' voices and concerns are considered in the policy making process.
-  Through this initiative, we continue to support our members in amplifying their impact—ensuring that together, we are a united voice for the scleroderma community.

# Healthcare

## Meetings with Members of European Parliament

In 2024, FESCA engaged in meetings with several Members of the European Parliament (MEPs), including Tomislav Sokol (EPP, Croatia), András Kulja (EPP, Hungary), Adam Jarubas (EPP, Poland), Oliver Schenck (EPP, Germany), as well as Michalis Hadjipantela (former Minister of Health, Cyprus). These discussions aimed to amplify the voice of scleroderma patients at the regional level, advocate for policy reform, and raise awareness about rare rheumatic diseases within the European Union. Central to these efforts was the push for improved public and medical understanding, as well as the urgent need for standardized, high-quality care across all EU Member States.

Scleroderma is one of several rare rheumatic diseases, alongside conditions such as vasculitis, lupus, and Sjögren's syndrome. Patients living with these diseases face a broad spectrum of unmet needs, largely due to their complex, multisystem nature and the limited resources allocated to their care.

These conditions often lead to diagnostic delays and fragmented care. Limited research and insufficient funding contribute to a lack of targeted, evidence-based treatments, often leaving patients with inadequate therapeutic options.

### Key Challenges for EU-Level Action

FESCA's discussions with MEPs highlighted several priority areas that require coordinated European action:

- Limited access to oxygen therapy
- The need for specialized care networks dedicated to rare rheumatic diseases
- Ensuring cross-board access and portability of data, as well interoperability of the platforms
- Endorsing an alliance of rare rheumatic diseases at EU level
- Ensuring that rare diseases remain a priority, in a landscape where there is an increasing focus on other chronic conditions, such as cancer or cardiovascular issues

As the umbrella organization for national scleroderma associations across Europe, FESCA plays a central role in advocacy and support. Through sustained advocacy at the EU level and direct support for our members, we continue to work toward lasting policy change and improved outcomes for patients throughout Europe.

## Research

FESCA is a key **reference in Systemic Sclerosis research, clinical practice, and the pharmaceutical sector**. We collaborate with various industry partners and maintain our presence in their projects and trials. FESCA consistently advocates for the patients' perspective and works tirelessly to safeguard their rights.

FESCA maintains a strong and ongoing collaboration with **EULAR** across various initiatives:

- Adherence Workinggroup
- ERS-EULAR CTDs-ILD Guidelines
- EULAR study group on micro circulation
- EULAR update of SSc recommendations
- EULAR Education Workinggroup
- EULAR PARE 2024 in Brussels



### EULAR PARE

In November 2024, the conference held in Brussels focused on key topics such as EULAR advocacy through the EULAR Manifesto Campaign and education initiatives aimed at fostering expanded Patient Research Partner (PRP) involvement in rheumatology research.

FESCA engaged in several working groups, including “Putting the EULAR Recommendations to Work,” which facilitated valuable discussions and practical insights. There were poster presentations, where representatives provided concise one-minute overviews, followed by opportunities for attendees to ask questions.

The conference spanned several days and featured a packed and enriching program, offering a comprehensive view of the current advancements and initiatives in rheumatology.

## Research

FESCA is working closely with multiple partners on a number of joint initiatives:

- **ERN ReCONNET**
  - Workinggroup on the digital lesions project
- **EURORDIS**
  - Workinggroup on CPGs and patient pathways
- **ELF-EUPFF**
  - Workinggroup on lung fibrosis
- **Boehringer Ingelheim** Patient Engagement Panel
- Partners in many **EU projects**
- Co-authors in many **scientific publications**
- **DITA Task Force**
- **Juvenile Scleroderma Symposium**
- **Juvenile Scleroderma Research**



### JUVENILE SCLERODERMA RESEARCH

FESCA actively contributed to the working group that developed the first consensus-based recommendations on the use of stem cell therapy for juvenile systemic sclerosis (jSSc). Their participation played an important role in shaping these pioneering guidelines, which mark a significant step forward in the treatment and management of this rare pediatric condition.

Emphasizes pediatric-specific disease characteristics and treatment responses. Offers tailored guidance for patient selection based on disease severity, progression, and failure of standard treatments.

## Directory of members

Currently, FESCA comprises 23 member organisations across 18 countries.

Country	Organisation	Country	Organisation
Austria	Sklerodermie Selbsthilfe e.V.	Israel	INBAR Association
Belgium	CIB-Liga vzw	Italy	AILS – Associazione Italiana Lotta alla Sclerodermia onlus
Belgium	APSB – Association des Patients Sclérodermiques de Belgique	Italy	ASSMAF – Associazione per lo studio della Sclerosi Sistemica e delle Malattie Fibrosanti
Bulgaria	Bulgarian Organization for Patients with Rheumatic Diseases- BOPRD	Italy	APMARR - Associazione Nazionale Persone con Malattie Reumatologiche e Rare
Croatia	HUOS – Hrvatska udruga oboljelih od sklerodermije	Italy	GILS – Gruppo Italiano per la Lotta alla Sclerodermia Padigione Litta
Cyprus	Αντιρευματικός Σύνδεσμος Κύπρου (Cyprus Antirheumatic Association)	Netherlands	Nationale vereniging voor LUPUS, APS, Sclerodermie en MCTD
Czech Republic	Revma liga Revmatologický ústav	Norway	Norsk Revmatikerforbund
Denmark	Sklerodermiforeningen	Portugal	ADPE – Associação Portuguesa de Doentes com Esclerodermia
Finland	Suomen Sklerodermayhdistys Ry	Portugal	Liga Portuguesa contra as Doenças Reumáticas
France	Association des Sclérodermiques de France	Romania	Asociatia Pacientilor cu Sclerodermie din Romania
Germany	Sklerodermie Selbsthilfe e.V.	Spain	AEE – Asociación Española de Esclerodermia
Germany	Scleroderma Liga e.V.	Sweden	The Swedish Rheumatism Association Reumatikerförbundet
Greece	ELEANA-Hellenic League Against Rheumatism	Switzerland	Sclerodermie.ch
Hungary	Országos Scleroderma Közhasznú Egyesület	United Kingdom	Scleroderma and Raynaud's UK



## Federation of European Scleroderma Associations (FESCA)

International Non-Profit Association

**Registration No:** FOJ 15454

**Email:** [info@fesca-scleroderma.eu](mailto:info@fesca-scleroderma.eu)

**Website:** [www.fesca-scleroderma.eu](http://www.fesca-scleroderma.eu)

### **Registered address:**

FESCA aisbl

Rue du Pont à Rieu 13 i

7500 Saint Maur BELGIUM

### **FESCA is member of:**

- EURORDIS
- Rare Diseases Europe EPF
- European Patients' Forum EULAR PARE

### **The Board**

- Sue Farrington- President
- Ilaria Galetti-Vice-President
- Linda Schraven - Secretary
- Annelise Rønnow - Communications Manager
- Monica Holmner - Board member

## **Support FESCA**

If you would like to support the work of the Federation of European Scleroderma Associations (FESCA), please consider making a donation.

You can donate directly through the FESCA website at [www.fesca-scleroderma.eu](http://www.fesca-scleroderma.eu).

## **What is Scleroderma?**

Systemic Sclerosis (SSc), also known as Scleroderma, is a rare, chronic and often progressive disease that affects the immune system, blood vessels, and connective tissue. Although it currently has no cure, it is neither contagious nor infectious, nor typically hereditary. The exact cause of Scleroderma remains unknown. While it is not directly inherited, there may be a slight familial predisposition in those with a history of rheumatic conditions. The disease manifests in various ways, including the thickening and hardening of the skin and potential involvement of internal organs, excluding the brain. Diagnosing Scleroderma can be challenging because its symptoms differ widely among individuals and progress at varying rates.

Scleroderma can develop at any age, but it most commonly appears between the ages of 25 and 55 and Raynaud's phenomenon is often the first noticeable sign. Scleroderma is rare in children and affects women four times more often than men. The severity of the disease can range from mild to life-threatening.

While there is no cure, effective treatments are available to manage symptoms and improve quality of life. Organ-specific therapies can significantly help patients, though pulmonary arterial hypertension (PAH) remains a leading cause of mortality in severe cases.

### **How Many People Have SSc?**

A disease is rare if it affects fewer than 5 out of 10,000 people. However, the global epidemiology of SSc has not been thoroughly studied. Prevalence estimates vary by country, though it is generally believed that 10% of a population experiences Raynaud's phenomenon, with 2–7% of these cases progressing to Scleroderma.



[info@fesca-scleroderma.eu](mailto:info@fesca-scleroderma.eu)



**Thank You to Our Sponsors**  
**We deeply appreciate the generous support of our sponsors**

